Human Immunodeficiency Virus
Conditions
Keywords
HIV, NNRTI Failure, HIV Infections
Brief summary
This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
Interventions
DRUGCapravirine
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female at least 18 years old * HIV RNA level \>1000 copies/mL at screening * CD4 \>50 cells/uL at screening * Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen * Patient has adequate hematology tests (absolute neutrophil count \>1000/uL, Platelets\>75,000uL, hemoglobin 9g/L) * Patient has adequate renal function (serum creatinine of \<1.5 upper limit of normal) * Patient has adequate liver function (AST, ALT, and bilirubin \< 2.5 upper limit of normal)
Exclusion criteria
* Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was \<50 copies) This exception does not include Viracept * Women who are pregnant or lactating
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective was to determine whether the addition of capravirine to a regimen of VIRACEPT and 2 new nucleoside reverse transcriptase inhibitors would provide a higher virologic response rate over 48 weeks | — |
| when compared to a 3-drug regimen without capravirine in patients who had experienced virologic failure while on a nonnucleoside reverse transcriptase inhibitor regimen. | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationship of HIV resistance (genotype and phenotype) to virologic response. | — |
| The immunologic response as determined by CD4 and CD8 absolute lymphocyte counts | — |
| The safety and tolerability of 2 doses of capravirine. | — |
| The pharmacokinetics of potential drug-drug interactions. | — |
| The population pharmacokinetics of capravirine and VIRACEPT | — |
| The difference between 2 doses of capravirine in terms of tolerability, efficacy, and pharmacokinetics | — |
Countries
France, Germany, Italy, South Africa, Spain, United States
Outcome results
None listed